Europe Laboratory Developed Tests Market Size

Europe Laboratory Developed Tests Market Size

Europe Laboratory Developed Tests Market size was valued at around USD 2.1 billion in 2023 and is estimated to grow at 6.1% CAGR from 2024 to 2032. Rising demand for infectious disease testing, increasing healthcare expenditure and focus on early disease detection and prevention are among the key attributes driving the laboratory developed tests (LDTs) market growth in the region. For instance, according to data released by the European Respiratory Virus Surveillance Summary in 2023, around half of the regional countries are experiencing increased levels of fever and cough and there is a sharp rise in the recorded numbers.

Similarly, a rise in the number of patients suffering from respiratory syncytial virus (RSV) is being observed each year in Europe. Thus, LDTs have played a critical role in detecting infections, monitoring transmission dynamics, and guiding public health responses in Europe for different infectious diseases.

Further, increasing adoption of next-generation sequencing (NGS) have revolutionized genomic analysis and enabled high-throughput sequencing of DNA and RNA. Europe has witnessed widespread adoption of NGS platforms in research, clinical diagnostics, and personalized medicine applications, driving the demand for LDTs based on sequencing technologies.

Laboratory developed tests (LDTs) refer to diagnostic tests that are developed, validated, and performed within a single laboratory. These tests are designed to detect a wide range of conditions, from infectious diseases to genetic disorders, and they are often used when commercial tests are not available or do not meet the specific needs of a patient population.